Nordic Life Science 1
Combinostics’ platform will hopefully enhance neu
rology departments worldwide Miguel Forte, former CEO, Zelluna FUNDING The two companies have entered into a development, license and supply agreement. The company has closed a EUR 3.9 million series A funding round that will see the company scale its platform for early-stage Alzheimer’s diagnosis to the US and Asia. THE ROUND WAS jointly-led by Industrifonden and NordicNinja VC, with Combinostics representing NordicNinja’s fifth deep tech investment over the past six months. “We will use this investment to ramp up R&D, build our US operations, and expand in Asia. We currently have a partner working on regulatory approval in Japan, and we are looking for a partner in China,” says Lennart Thurfjell, CEO, Combinostics. “Combinostics has built a product platform from cutting-edge research that will enhance neurology departments worldwide. Their platform supports improved diagnostic accuracy and treatment choice by combining all relevant biomarkers with advanced brain image quantification, leading to improved health in neurology patients,” says Patrik Sobocki, Investment Manager, Industrifonden. HROUGH THE PARTNERSHIP with Glycostem, Zelluna is enabling its TCR-NK approach BUSINE S S D E A L RECIPHARM TO ACQUIRE CONSORT MEDICAL THE BOARD OF CONSORT HAS CONFIRMED ITS UNANIMOUS INTENTION TO RECOMMEND A CASH OFFER FOR AN EQUITY VALUE OF GBP 505 MILLION. THE ENLARGED RECIPHARM GROUP is set to become a top five global CDMO, able to offer integrated device development and supply combined with commercial scale finished dose manufacturing. “I am excited at the prospect of combining Recipharm with Consort. The enlarged group will be able to provide finished dose forms in Bespak’s key technologies and provide customers with a far more integrated approach. The Aesica business will further expand our capabilities and capacities in both API and finished dose manufacturing, whilst providing access to a new customer base,” says Thomas Eldered, CEO. with the potential to target a broader repertoire of tumor associated antigens by targeting NK-cells with TCRs for treatment of patients with solid cancers, it states. Zelluna Immunotherapy will lead the development and commercialization of TCR-NK products with its TCRs and TCR development competence. Glycostem will contribute by manufacturing clinical grade umbilical cordderived NK-cells, NK-cell expertise, product process development, and clinical and commercial supply. Zelluna and Glycostem will be able to manufacture upfront a large number of patient doses to store and ship to clinical sites upon demand in an “off-theshelf” manner, they state. PHOTO JUSSI MATTILA